Each time the U.S. Supreme Court has addressed patent eligibility, the law surrounding what can and cannot be patented has become murkier. Most recently, the wake of the Supreme Court’s Alice ruling has led to irreconcilable...more
Written Description of Therapeutic Efficacy -
In two 2019 rulings, the Federal Circuit invoked the “written description requirement” of 35 U.S.C. § 112 to require evidentiary support for therapeutic efficacy. Now that the...more
2/24/2021
/ Appeals ,
Copyright ,
Defend Trade Secrets Act (DTSA) ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Misappropriation ,
Patent-Eligible Subject Matter ,
Pharmaceutical Patents ,
Section 101 ,
Social Media ,
Trade Secrets ,
USPTO ,
Written Descriptions